Biotech executives at BIO 2026 confronted mounting concerns over Chinese competition, the uncertain profitability of AI-driven drug discovery, and political threats to U.S. drug pricing policies. These challenges underscore a sector navigating significant regulatory, competitive, and technological headwinds. — "Prescription Prices Ver3" by ccPixs.com is licensed under CC BY 2.0. To view a copy of this license, visit https://creativecommons.org/licenses/by/2.0/. (CC BY 2.0)
MD, MPH, PhD. Editor-in-Chief, Georgian Medical Journal (GMJ). Professor and Head, School of Public Health, David Tvildiani Medical University (DTMU), Tbilisi, Georgia. Chair, Public Health Institute of Georgia (PHIG). President, Accréditation Sans Frontières (ASF), Paris. Secretary/Treasurer, UEMS Section of Public Health. WHO Consultant, Health and Migration, Geneva. Former Member, UN Secretary-General's Independent Accountability Panel for Every Woman, Every Child, Every Adolescent (IAP-EWEC, 2016–2021). ORCID: 0000-0001-7609-4515.
